Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2020.08.051
Abstract: BACKGROUND Up to 15% of patients with major depressive disorder (MDD) attempt suicide and up to 2% complete suicide. This was a post-hoc analysis aimed to evaluate the risk of suicide ideation and behavior associated… read more here.
Keywords: adjunctive pimavanserin; ideation; analysis; study ... See more keywords
Pimavanserin for bipolar disorder
Sign Up to like & getrecommendations! Published in 2022 at "Bipolar Disorders"
DOI: 10.1111/bdi.13191
Abstract: Table 1 summarizes the key characteristics of the three patients with bipolar illness. Figure 1 provides a partial life chart of patient 1 over the time that she has been diagnosed with Parkinson’s disease; the… read more here.
Keywords: function; oxcarbazepine; pimavanserin bipolar; patient ... See more keywords
Editors' Note: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000013041
Abstract: Dr. Hwang et al. examined the risk of hospitalization and death associated with pimavanserin use in a retrospective cohort study of 2,186 pimavanserin users with Parkinson disease (PD) compared with 18,212 nonusers with PD, all… read more here.
Keywords: mortality; risk hospitalization; disease; pimavanserin ... See more keywords
Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000013042
Abstract: Hwang et al.1 recently published a retrospective analysis of the risk of hospitalization or mortality in patients with Parkinson disease (PD) using pimavanserin in long-term care facilities. However, the study design and cohort selection do… read more here.
Keywords: parkinson disease; reader response; risk hospitalization; pimavanserin ... See more keywords
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000013043
Abstract: We respectfully disagree with Subbiah et al. in their criticism of our study.1 To overcome the lack of dedicated International Classification of Diseases codes for Parkinson disease (PD) psychosis, we accrued patients with PD and… read more here.
Keywords: author response; parkinson disease; pimavanserin; disease ... See more keywords
Effect of Pimavanserin on the Respiratory Arousal Threshold from Sleep: A Randomized Trial.
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the American Thoracic Society"
DOI: 10.1513/annalsats.202205-419oc
Abstract: RATIONALE A low respiratory arousal threshold is a key endotype responsible for obstructive sleep apnea (OSA) pathogenesis. Pimavanserin is an antiserotoninergic capable of suppressing CO2-mediated arousals without affecting the respiratory motor response in animal models,… read more here.
Keywords: arousal threshold; effect; osa severity; arousal ... See more keywords
Quantification of Pimavanserin in Bulk and Tablet Dosage Form Using A Stability Indicating High Performance Liquid Chromatographic Method
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceutical Sciences"
DOI: 10.15171/ps.2018.42
Abstract: Background: Pimavanserin, an antipsychotic agent, is used to treat patients suffering with Parkinson's disease. Till now no stability indicating reverse phase HPLC method was reported for the quantification of pimavanserin in bulk and tablet dosage… read more here.
Keywords: pimavanserin bulk; stability indicating; method; quantification pimavanserin ... See more keywords
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2021.27.6.785
Abstract: BACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on… read more here.
Keywords: neurology; parkinson; foundation; disease ... See more keywords
Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2022.919778
Abstract: Background Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis. Aim We aimed to evaluate motor-… read more here.
Keywords: cognition related; placebo; motor cognition; pimavanserin ... See more keywords